JP2022530503A - 遺伝子操作された微生物 - Google Patents
遺伝子操作された微生物 Download PDFInfo
- Publication number
- JP2022530503A JP2022530503A JP2021563687A JP2021563687A JP2022530503A JP 2022530503 A JP2022530503 A JP 2022530503A JP 2021563687 A JP2021563687 A JP 2021563687A JP 2021563687 A JP2021563687 A JP 2021563687A JP 2022530503 A JP2022530503 A JP 2022530503A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pharmaceutical composition
- composition according
- live
- genetically engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 244000005700 microbiome Species 0.000 title abstract description 183
- 241000894006 Bacteria Species 0.000 claims abstract description 363
- 239000000203 mixture Substances 0.000 claims abstract description 300
- 238000000034 method Methods 0.000 claims abstract description 229
- 230000000694 effects Effects 0.000 claims abstract description 107
- 210000004027 cell Anatomy 0.000 claims description 1276
- 239000008194 pharmaceutical composition Substances 0.000 claims description 228
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 179
- 108090000623 proteins and genes Proteins 0.000 claims description 177
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 165
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 110
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 104
- 230000001225 therapeutic effect Effects 0.000 claims description 98
- 230000001580 bacterial effect Effects 0.000 claims description 93
- 201000010099 disease Diseases 0.000 claims description 68
- 102000004190 Enzymes Human genes 0.000 claims description 66
- 108090000790 Enzymes Proteins 0.000 claims description 66
- 229940088598 enzyme Drugs 0.000 claims description 66
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims description 61
- 239000007787 solid Substances 0.000 claims description 58
- 108010078791 Carrier Proteins Proteins 0.000 claims description 54
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 201000011252 Phenylketonuria Diseases 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 39
- 239000004475 Arginine Substances 0.000 claims description 37
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 37
- 150000001483 arginine derivatives Chemical class 0.000 claims description 34
- 238000005259 measurement Methods 0.000 claims description 34
- 208000035475 disorder Diseases 0.000 claims description 33
- 239000007983 Tris buffer Substances 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 32
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 31
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 30
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 28
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 28
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 28
- 230000001939 inductive effect Effects 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 28
- 241000588724 Escherichia coli Species 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 27
- 230000007812 deficiency Effects 0.000 claims description 25
- 230000001093 anti-cancer Effects 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- 101710149879 Arginine repressor Proteins 0.000 claims description 19
- 239000002158 endotoxin Substances 0.000 claims description 19
- 206010020575 Hyperammonaemia Diseases 0.000 claims description 17
- 101150077062 pal gene Proteins 0.000 claims description 16
- 230000000968 intestinal effect Effects 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 15
- 210000000936 intestine Anatomy 0.000 claims description 14
- 230000001331 thermoregulatory effect Effects 0.000 claims description 13
- 241000186660 Lactobacillus Species 0.000 claims description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 230000002485 urinary effect Effects 0.000 claims description 12
- 101710095468 Cyclase Proteins 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 230000002496 gastric effect Effects 0.000 claims description 10
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 108010032178 Amino-acid N-acetyltransferase Proteins 0.000 claims description 9
- 102000007610 Amino-acid N-acetyltransferase Human genes 0.000 claims description 9
- 206010021143 Hypoxia Diseases 0.000 claims description 9
- 230000001146 hypoxic effect Effects 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 7
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 7
- 241000606125 Bacteroides Species 0.000 claims description 6
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 150000008575 L-amino acids Chemical class 0.000 claims description 6
- 239000004098 Tetracycline Substances 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 229940023064 escherichia coli Drugs 0.000 claims description 6
- 229960002180 tetracycline Drugs 0.000 claims description 6
- 229930101283 tetracycline Natural products 0.000 claims description 6
- 235000019364 tetracycline Nutrition 0.000 claims description 6
- 150000003522 tetracyclines Chemical class 0.000 claims description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 5
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 5
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000004020 luminiscence type Methods 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 108700005389 3-methylcrotonyl CoA carboxylase 1 deficiency Proteins 0.000 claims description 3
- 201000008000 3-methylcrotonyl-CoA carboxylase deficiency Diseases 0.000 claims description 3
- 206010062695 Arginase deficiency Diseases 0.000 claims description 3
- 208000034318 Argininemia Diseases 0.000 claims description 3
- 102000015790 Asparaginase Human genes 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 3
- 101710113083 Carbamoyl-phosphate synthase Proteins 0.000 claims description 3
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 3
- 208000005024 Castleman disease Diseases 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- 208000010334 End Stage Liver Disease Diseases 0.000 claims description 3
- 208000007698 Gyrate Atrophy Diseases 0.000 claims description 3
- 208000034596 Gyrate atrophy of choroid and retina Diseases 0.000 claims description 3
- 208000000420 Isovaleric acidemia Diseases 0.000 claims description 3
- 201000004458 Myoma Diseases 0.000 claims description 3
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 3
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 3
- 208000012868 Overgrowth Diseases 0.000 claims description 3
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 3
- 229960003272 asparaginase Drugs 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 3
- 238000010322 bone marrow transplantation Methods 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000011444 chronic liver failure Diseases 0.000 claims description 3
- 238000002574 cystoscopy Methods 0.000 claims description 3
- 230000010339 dilation Effects 0.000 claims description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 3
- 201000011286 hyperargininemia Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 208000012268 mitochondrial disease Diseases 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 235000016236 parenteral nutrition Nutrition 0.000 claims description 3
- 201000002511 pituitary cancer Diseases 0.000 claims description 3
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 3
- 210000001635 urinary tract Anatomy 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- NXOIMAMHRHDCFR-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrole-2-carboxylic acid Chemical compound OC(=O)C1CC=CN1 NXOIMAMHRHDCFR-UHFFFAOYSA-N 0.000 claims description 2
- BOEUHAUGJSOEDZ-UHFFFAOYSA-N 2-amino-5,6,7,8-tetrahydro-1h-pteridin-4-one Chemical compound N1CCNC2=C1C(=O)N=C(N)N2 BOEUHAUGJSOEDZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010010071 Coma Diseases 0.000 claims description 2
- 208000018542 Dihydropteridine reductase deficiency Diseases 0.000 claims description 2
- 208000002603 Dopa-responsive dystonia Diseases 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 108700043217 N-acetyl glutamate synthetase deficiency Proteins 0.000 claims description 2
- 206010071092 N-acetylglutamate synthase deficiency Diseases 0.000 claims description 2
- 206010028729 Nasal cavity cancer Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 241000078013 Trichormus variabilis Species 0.000 claims description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 201000002454 adrenal cortex cancer Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 201000010235 heart cancer Diseases 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 230000002631 hypothermal effect Effects 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 230000036244 malformation Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 201000004012 propionic acidemia Diseases 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 208000037968 sinus cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 230000004143 urea cycle Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 229960000604 valproic acid Drugs 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 208000005223 Alkalosis Diseases 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000002340 alkalosis Effects 0.000 claims 1
- KDZOASGQNOPSCU-UHFFFAOYSA-N argininosuccinate Chemical compound OC(=O)C(N)CCCN=C(N)NC(C(O)=O)CC(O)=O KDZOASGQNOPSCU-UHFFFAOYSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 239000001390 capsicum minimum Substances 0.000 claims 1
- 230000004452 decreased vision Effects 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 201000003694 methylmalonic acidemia Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 113
- 238000004163 cytometry Methods 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 description 150
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 58
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 36
- 229960003121 arginine Drugs 0.000 description 36
- 229910021529 ammonia Inorganic materials 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 27
- 101150038944 dacA gene Proteins 0.000 description 27
- 101150014046 disA gene Proteins 0.000 description 26
- XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 26
- 210000004379 membrane Anatomy 0.000 description 24
- 239000012528 membrane Substances 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 23
- -1 hydrogen hydrogen Chemical class 0.000 description 23
- 238000000338 in vitro Methods 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000012669 liquid formulation Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000000170 cell membrane Anatomy 0.000 description 18
- 125000004122 cyclic group Chemical group 0.000 description 18
- 239000006041 probiotic Substances 0.000 description 18
- 235000018291 probiotics Nutrition 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- 230000035899 viability Effects 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- 239000007850 fluorescent dye Substances 0.000 description 16
- BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 16
- 238000010186 staining Methods 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 101150035123 pme gene Proteins 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 230000000529 probiotic effect Effects 0.000 description 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 14
- 230000001332 colony forming effect Effects 0.000 description 13
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 244000052616 bacterial pathogen Species 0.000 description 11
- 238000004108 freeze drying Methods 0.000 description 11
- 230000035699 permeability Effects 0.000 description 11
- 101150072314 thyA gene Proteins 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 description 9
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 description 9
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 238000013268 sustained release Methods 0.000 description 9
- 239000012730 sustained-release form Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000001903 2-oxo-3-phenylpropanoic acid Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- DEDGUGJNLNLJSR-UHFFFAOYSA-N alpha-hydroxycinnamic acid Natural products OC(=O)C(O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000006177 biological buffer Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 229940127557 pharmaceutical product Drugs 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 229940113082 thymine Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 229940044665 STING agonist Drugs 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 150000002994 phenylalanines Chemical class 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 4
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 101100465553 Dictyostelium discoideum psmB6 gene Proteins 0.000 description 4
- 101100352026 Escherichia coli (strain K12) pheP gene Proteins 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000007993 MOPS buffer Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 4
- 239000007990 PIPES buffer Substances 0.000 description 4
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 4
- 241000588769 Proteus <enterobacteria> Species 0.000 description 4
- 101100169519 Pyrococcus abyssi (strain GE5 / Orsay) dapAL gene Proteins 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 4
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 235000013351 cheese Nutrition 0.000 description 4
- 229960002173 citrulline Drugs 0.000 description 4
- 235000013477 citrulline Nutrition 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 101150011371 dapA gene Proteins 0.000 description 4
- 101150064923 dapD gene Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000016097 disease of metabolism Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000007407 health benefit Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000012792 lyophilization process Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 210000001322 periplasm Anatomy 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 4
- 238000000782 polymeric membrane extraction Methods 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 241000194036 Lactococcus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101150072055 PAL1 gene Proteins 0.000 description 3
- 101150081344 PAL3 gene Proteins 0.000 description 3
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 101150080283 RIM8 gene Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 101100192827 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PXA1 gene Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960000510 ammonia Drugs 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 101150010999 aroP gene Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 235000021001 fermented dairy product Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000021127 solid diet Nutrition 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 208000030954 urea cycle disease Diseases 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 2
- 206010000804 Acute hepatic failure Diseases 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000034263 Amino acid transporters Human genes 0.000 description 2
- 108050005273 Amino acid transporters Proteins 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229930182832 D-phenylalanine Natural products 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 101100244111 Dictyostelium discoideum stlA gene Proteins 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100034047 Heat shock factor protein 4 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241000588771 Morganella <proteobacterium> Species 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- 241000588768 Providencia Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000481518 Ralstonia eutropha H16 Species 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000836 acute liver failure Toxicity 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 201000003554 argininosuccinic aciduria Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000000959 cryoprotective effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 101150076563 malP gene Proteins 0.000 description 2
- 239000013586 microbial product Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 101150101950 pheP gene Proteins 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- ALEVUYMOJKJJSA-UHFFFAOYSA-N 4-hydroxy-2-propylbenzoic acid Chemical compound CCCC1=CC(O)=CC=C1C(O)=O ALEVUYMOJKJJSA-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 206010058298 Argininosuccinate synthetase deficiency Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010446 CRISPR interference Methods 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 201000011297 Citrullinemia Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150082208 DIABLO gene Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010014961 Eosinophilic myocarditis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 101100378572 Escherichia coli (strain K12) agaI gene Proteins 0.000 description 1
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 108091026922 FnrS RNA Proteins 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102100033945 Glycine receptor subunit alpha-1 Human genes 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101000996297 Homo sapiens Glycine receptor subunit alpha-1 Proteins 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- 101000986595 Homo sapiens Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101150108784 INSB gene Proteins 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000021330 IgG4-related disease Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000000599 Ornithine Carbamoyltransferase Deficiency Disease Diseases 0.000 description 1
- 206010052450 Ornithine transcarbamoylase deficiency Diseases 0.000 description 1
- 208000035903 Ornithine transcarbamylase deficiency Diseases 0.000 description 1
- 102100028200 Ornithine transcarbamylase, mitochondrial Human genes 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010092494 Periplasmic binding proteins Proteins 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038664 Respiratory alkalosis Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010071574 Testicular autoimmunity Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940078654 antiemetics and antinauseants serotonin (5ht3) antagonists Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 101150044616 araC gene Proteins 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003459 common hepatic duct Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 229950010333 exalamide Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 108700036927 isovaleric Acidemia Proteins 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229940102226 oral flakes Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000011278 ornithine carbamoyltransferase deficiency Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 208000014965 pancolitis Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008529 pathological progression Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 108010078226 phenylalanine oxidase Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 208000033685 pterin-4 alpha-carbinolamine dehydratase 1 deficiency Diseases 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 101150061689 rsmI gene Proteins 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y403/00—Carbon-nitrogen lyases (4.3)
- C12Y403/01—Ammonia-lyases (4.3.1)
- C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
- G01N15/075—Investigating concentration of particle suspensions by optical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
Abstract
Description
ビフィドバクテリウムインファンティス、ビフィドバクテリウムロングム、クロストリジウム・ブチリカム、エンテロコッカス フェシウム、大腸菌、ラクトバチルス アシドフィルス、ラクトバチルス ブルガリクス、ラクトバチルス カゼイ、ラクトバチルス ジョンソニー、ラクトバチルス パラカセイ、ラクトバチルス プランタルム、ラクトバチルス ロイテリ、ラクトバチルス ラムノサス、ラクトコッカス ラクチス、およびサッカロマイセス ブラウディが挙げられるが、これらに限定されない。(Sonnenborn他、2009、Dinleyici他、2014、米国特許第6,835,376号、米国特許第6,203,797号、米国特許第5,589,168号、米国特許第7,731,976号)。自然病原性細菌は、病原性を減少または除去するように遺伝子操作され得る。
生菌数測定
製法
凍結乾燥
噴霧乾燥
凍結液
本開示は、人工微生物、例えば遺伝子操作された細菌の生細胞数を決定する方法、および組成物、製剤、投薬、人工微生物、例えば遺伝子操作された細菌を製造する方法を、例えば生細胞計数法を用いて決定する方法を提供する。人口微生物、例えば、生細胞計数法を用いてアッセイされ得る、遺伝子操作された微生物、組成物、およびその製剤は、WO2016090343、WO2016200614、WO2017139697、WO20160183531、WO2017087580、WO2016141108、WO2017074566、WO2017136792、WO2017136795、WO20180129404、WO2019014391、WO2016210384、WO2017123418、WO2017123676、WO2016183531、WO2018237198、WO2016201380、US20170216370、およびWO2017040719に記載され、これらの内容は、その全体が参照により本明細書に組み込まれる。
いくつかの実施形態において、本開示は、疾患もしくは障害、例えば癌、または高フェニルアラニン血症に関連する疾患、例えばPKU、または高アンモニア血症に関連する疾患、例えばUCDもしくは癌を治療、管理、改善、および/または予防するために使用可能な薬学的組成物を提供する。1つ以上の人工微生物、例えば遺伝子操作された細菌を含む本発明の薬学的組成物は、単独で、または予防薬、治療薬剤、および/または薬学的に許容可能な担体と組み合わせて提供される。ある実施形態において、医薬組成物は、本明細書に記載の遺伝子改変を含むように操作される微生物、例えばバクテリアの1つの種、株、またはサブタイプを含む。別の実施形態では、医薬組成物は、それぞれが本明細書に記載される遺伝子改変を含むように操作される、微生物、例えば細菌の2つ以上の種、株、および/またはサブタイプを含む。
いくつかの実施態様において、固形製剤、例えば固形経口製剤は、人工微生物、例えば、dacA、または改変アルギニン生合成経路またはフェニルアラニン代謝酵素、例えばPALおよび/またはLAADを発現する、遺伝子操作された細菌の約1×1012の生細胞、約1.1×1012の生細胞、約1.2×1012の生細胞、約1.3×1012の生細胞、約1.4×1012の生細胞、約1.9×1012の生細胞、約2×1012の生細胞、約2.1×1012の生細胞、約2.2×1012の生細胞、約2.3×1012の生細胞、約2.4×1012の生細胞、約2.5×1012の生細胞、約2.6×1012の生細胞、約2.7×1012の生細胞、約2.8×1012の生細胞、約2.9×1012の生細胞、約3×1012の生細胞、約3.1×1012の生細胞、約3.2×1012の生細胞、約3.3×1012の生細胞、約3.4×1012の生細胞、約3.5×1012の生細胞、約3.6×1012の生細胞、約3.7×1012の生細胞、約3.8×1012の生細胞、約3.9×1012の生細胞、約4×1012の生細胞、約4.1×1012の生細胞、約4.2×1012の生細胞、約4.3×1012の生細胞、約4.4×1012の生細胞、約4.5×1012の生細胞、約4.6×1012の生細胞、約4.7×1012の生細胞、約4.8×1012の生細胞、約4.9×1012生細胞、または約5×1012の生細胞を含み、固形製剤、例えば固形経口製剤の活性は、任意的にTCA、HAまたは標識D5-HA、PPA、血中フェニルアラニン、アンモニア、アルギニン、シトルリン、サイクリックジヌクレオチド、サイクリックジーAMP、または他の適切な測定、例えば制御との比較によって決定される。
[表1]
治療方法
バクテリアの構築
処理
凍結乾燥
噴霧乾燥
凍結液
生細胞数測定
凍結液体、凍結乾燥又は噴霧乾燥バクテリアを含む製剤のin vitro活性
In Vitro シミュレーション(IVS) 腸モデル
[表3]
[表4]
[表5]
[表6]
生細胞数及びCFU方法
生細胞数及びCFU方法
非ヒト霊長類(NHP)研究
In Vivo SYNB1618
凍結乾燥菌体を含む製剤の安定性
PKU菌株の生菌数測定
UCD及び癌治療細菌株の生細胞数測定
生細胞の直線範囲の判定/mL
本開示は、所望の治療用分子を産生するための1つ以上の遺伝子を含む操作された微生物(例えば、遺伝子操作された細菌)ならびにその組成物および製剤に関する。一態様では、例えば生細胞カウンティング法を使用して、細菌、組成物、および製剤の活性を特徴付ける、投与する、および決定するための方法が提供される。生細胞カウンティング法が、細菌サンプル中に存在する生細胞の数を測定するために使用され得る。具体的には、生きている操作された微生物(例えば、遺伝子操作された細菌細胞)の数を決定するため、ならびに操作された微生物(例えば、遺伝子操作された細菌)の活性を投与および/または測定するために、生細胞カウンティング法が使用され得る。
いくつかの実施形態では、1つ以上の治療用遺伝子を含む操作された微生物(例えば、遺伝子操作された細菌)ならびにその組成物および製剤は、本明細書に開示される活性を特徴付ける、投与する、および決定するための方法(例えば、生細胞カウンティング)を使用して製造される。本開示に従って製造され得る例示的な微生物(例えば細菌)ならびに組成物および製剤は、WO2016090343、WO2016200614、WO2017139697、WO2016183531、WO2017087580、WO2016141108、WO2017074566、WO2017136792、WO2017136795、WO2018129404、WO2019014391、WO2016210384、WO2017123418、WO2017123676、WO2016183531、WO2018237198、WO2016201380、US20170216370、およびWO2017040719において提供されており、これらの内容は、その全体が参照により本明細書に援用される。
いくつかの実施形態では、本開示は、凍結乾燥された操作された微生物(例えば、凍結乾燥された遺伝子操作された細菌)を製造するための方法を提供する。いくつかの実施形態では、操作された凍結乾燥された微生物(例えば、凍結乾燥された細菌)を製造するための方法は、細菌の凍結組成物と少なくともほぼ等しい生存率および効力をもたらす。
いくつかの実施形態では、噴霧乾燥プロセスは、細胞を噴霧乾燥緩衝液に懸濁することを含む。いくつかの実施形態では、噴霧乾燥プロセスは、110~150℃の入口温度を有し、40~80℃の出口温度を目標とする2流体ノズルを通して細胞を噴霧乾燥することを含み、その結果、自由流動性の粉末が得られる。いくつかの実施形態では、入口温度は120~135℃である。いくつかの実施形態では、目標とする出口温度は60℃である。
いくつかの実施形態では、凍結液体プロセスは、細胞を凍結保護緩衝液に懸濁することと、-20℃~200℃で凍結させることを含む。いくつかの実施形態では、細胞懸濁液は-80℃で凍結される。
本開示は、例えば生細胞カウンティング法を使用して、操作された微生物(例えば、遺伝子操作された細菌)の生細胞カウントを決定する方法、および組成物、製剤、投与、操作された微生物(例えば、遺伝子操作された細菌)を製造する方法を提供する。例えば生細胞カウンティング法を使用してアッセイされ得る操作された微生物(例えば、遺伝子操作された細菌)、ならびにその組成物および製剤は、WO2016090343、WO2016200614、WO2017139697、WO20160183531、WO2017087580、WO2016141108、WO2017074566、WO2017136792、WO2017136795、WO20180129404、WO2019014391、WO2016210384、WO2017123418、WO2017123676、WO2016183531、WO2018237198、WO2016201380、US20170216370、およびWO2017040719に記載されており、これらの内容は、その全体が参照により本明細書に援用される。
いくつかの実施形態では、本開示は、疾患または障害(例えば、癌;または高フェニルアラニン血症に関連する疾患(例:PKU);または高アンモニア血症に関連する疾患(例:UCDまたは癌))を処置、管理、改善、および/または予防するために使用され得る医薬組成物を提供する。1つ以上の操作された微生物(例えば、遺伝子操作された細菌)を単独で、または予防剤、治療剤および/もしくは薬学的に許容される担体と組み合わせて含む本発明の医薬組成物が提供される。特定の実施形態では、医薬組成物は、本明細書に記載の遺伝子改変を含むように操作された、微生物(例えば細菌)の1つの種、株、または亜型を含む。別の実施形態では、医薬組成物は、本明細書に記載の遺伝子改変を含むようにそれぞれ操作された、微生物(例えば細菌)の2つ以上の種、株、および/または亜型を含む。
いくつかの実施形態では、本開示は、疾患または障害を患っている対象を処置するための方法であって、本明細書に開示される活性を特徴付ける、投与する、および決定するための方法(例えば、生細胞カウンティング法)を使用して測定、投与、および/または製造された、操作された微生物(例えば、遺伝子操作された細菌)を投与することを含む、方法を提供する。
大腸菌NissleにおけるPALの誘導性産生を促進するために、アナベナ・バリアビリス(Anabaena variabilis)のPAL遺伝子(「PAL1」)またはフォトラブダス・ルミネッセンス(Photorhabdus luminescens)のPAL遺伝子(「PAL3」)、ならびに転写および翻訳要素を合成し(Gen9、ケンブリッジ、マサチューセッツ州)、ベクターpBR322にクローニングした。PAL遺伝子は誘導性プロモーターの制御下に置かれた。低コピーおよび高コピープラスミドが、誘導性FNRプロモーターまたはTetプロモーターの制御下でPAL1およびPAL3のそれぞれに対して作製された。本明細書に記載のプラスミドのそれぞれを、以下のステップに従って本明細書に記載の試験のために、大腸菌(例えば、大腸菌Nissle)に形質転換した。すべてのチューブ、溶液、およびキュベットは4℃に予め冷却された。大腸菌Nissleの一晩培養物を、アンピシリンを含む5mLの溶原性ブロス(LB)で1:100に希釈し、OD600が0.4~0.6に達するまで増殖させた。次に、大腸菌細胞を2000rpm、4℃で5分間遠心分離し、上清を除去し、細胞を4℃の水1mLに再懸濁した。大腸菌を2000rpm、4℃で5分間再び遠心分離し、上清を除去し、細胞を4℃の水0.5mLに再懸濁した。大腸菌を2000rpm、4℃で5分間再び遠心分離し、上清を除去し、最終的に細胞を4℃の水0.1mLに再懸濁した。エレクトロポレーターを2.5kVに設定した。プラスミド(0.5μg)を細胞に加え、ピペッティングにより混合し、ピペットで滅菌した冷却キュベットに入れた。乾燥キュベットをサンプルチャンバーに入れ、電気パルスを印可した。直ちに1mLの室温SOC培地を加え、混合物を培養チューブに移し、37℃で1時間インキュベートした。アンピシリンを含むLBプレート上に細胞を広げ、一晩インキュベートした。
凍結乾燥
発酵および細胞を凍結乾燥緩衝液に入れるための下流プロセスの後、細胞懸濁材料を15mmの充填深さで凍結乾燥トレイにロードする。凍結乾燥器を使用して次のサイクルを実行する:-40℃で材料を凍結し、-15℃で一次乾燥し、5℃で二次乾燥する。凍結乾燥サイクルの終了後、凍結乾燥ケーキを80メッシュのスクリーンを通してふるい分け、その結果、自由流動性の粉末が得られる。
発酵および細胞を噴霧乾燥緩衝液に入れるための下流プロセスの後、120~135℃の入口温度を有し、60℃の出口温度を目標とする2流体ノズルを通して細胞懸濁液を噴霧乾燥し、自由流動性の粉末にする。
発酵および細胞を凍結保護緩衝液に入れるための下流プロセスの後、細胞懸濁液を-80℃で凍結する。
Nexcelom社のセロメーター(Cellometer)を使用して、生細胞カウントおよび生存率を求めた。凍結液体中に細菌を含む製剤については、サンプルを37℃の水浴で解凍した。凍結乾燥および噴霧乾燥した細菌を含む製剤については、1gをバイアルに量り取り、6mLのPBSで再水和した。次に、すべての細胞サンプルをPBSで1:1000に希釈し、さらにPBSまたはHBSS中のSytox green染色液で1:1に希釈した(合計1:2000希釈)。次に、この希釈液4μLをセロメーター(Cellometer)スライドに移した。スライドをセロメーター(Cellometer)に置き、明視野および蛍光画像を取得した。明視野で検出された細胞の数(総細胞)と蛍光で検出された細胞の数(非生細胞)の差から、生細胞カウントを算出した。生存率は、生細胞の数/総細胞の数として算出された。
実施例2に開示された方法に従って調製された凍結乾燥、凍結液体および噴霧乾燥細菌を含む細菌の組成物は、in vitroでの活性について特性評価された。表2は、プロセス1(凍結液体)またはプロセス2(固体バッチ、凍結乾燥)によって調製されたフェニルアラニン代謝細菌の例示的な特性を示す。
操作された細菌株の生存率および代謝活性を特徴付け、in vivoでの機能を予測するために、in vitroシミュレーション(IVS)消化管モデルを設計して、酸素濃度、胃および膵臓の酵素、胆汁など、ヒトの胃腸通過の重要な側面をシミュレートした。IVSモデルは、胃、小腸、および結腸の状態をシミュレートするように設計された96ウェルマイクロプレート形式の一連のインキュベーションを含む(図9)。フェニルケトン尿症の処置のために設計された操作された菌株を試験するために、シミュレートされた胃および小腸が検討された。IVSモデルの胃および小腸部分は、Minekus et al.(2014年)A standardised static in vitro digestion method suitable for food-an international consensusから採用された。
試験の少なくとも4日前から、非ナイーブ(non-naive)ホモ接合の雌のBTBR-Pahenu2/enu2マウス(約15~25週齢)に、フェニルアラニンを含まない固形飼料と0.5g/Lのフェニルアラニンを添加した水とを与えた。1日目に、マウスの体重を測定し、体重に基づいてランダムに群に分けた。次に、マウスに細菌を経口投与し、直ちに代謝ケージに移した。最初の細菌投与の1時間後と2時間後に、それぞれ2回の追加投与を行った。最初の細菌投与の3時間後、総尿サンプルを収集し、その体積を記録した。試験終了後、動物をホームケージに戻した。
試験の少なくとも4日前から、非ナイーブ(non-naive)ホモ接合の雌のBTBR-Pahenu2/enu2マウス(約12~22週齢)に、フェニルアラニンを含まない固形飼料と0.5g/Lのフェニルアラニンを添加した水とを与えた。1日目に、マウスの体重を測定し、体重に基づいてランダムに群に分けた。次に、マウスに細菌を経口投与し、直ちに代謝ケージに移した。最初の細菌投与の1時間後と2時間後に、それぞれ2回の追加投与を行った。最初の細菌投与の3時間後、総尿サンプルを収集し、その体積を記録した。試験終了後、動物をホームケージに戻した。
約2~5歳の雄の非ナイーブ(non-naive)カニクイザル10匹をランダムに2つのグループ(n=5)に分け、一晩絶食させた。投与前に、ベースラインのフェニルアラニン濃度用に血漿を収集した。動物は、採尿用の清潔な収集パンで分離された。次に、500g/Lのペプトン11mL、0.36Mの重炭酸ナトリウム5mL、および凍結液体SYNB1618(SYNB1618バッチA)または凍結乾燥SYNB1618のいずれかを各動物に投与した(1回投与あたり1.3×1011生細胞)。投与後0.5、1、2、4および6時間後に血漿サンプルを収集した。投与後6時間の終了時に、尿の総量を測定し、記録し、そして収集した。
試験の少なくとも4日前から、野生型で雌の非ナイーブ(non-naive)C57Bl/6マウス(約14週齢)に、フェニルアラニンを含まない固形飼料と0.5g/Lのフェニルアラニンを添加した水とを与えた。1日目に、マウスの体重を測定し、体重に基づいてランダムに群に分けた。次に、マウスに細菌を経口投与し、直ちに代謝ケージに移した。最初の細菌投与の1時間後と2時間後に、それぞれ2回の追加投与を行った。最初の細菌投与の3時間後、尿サンプルを収集し、その総体積を記録した。試験終了後、動物をホームケージに戻した。
安定性試験は、SYNB1618原薬製剤および製剤について、5±3℃および25±5℃/60±5%RHで6ヵ月間実施される。試験の開始を、サンプルが適切な保管条件に置かれた日として定めた。
細菌株およびSytox Green染色液は、既述のとおり調製された。SYNB1618の3つのバッチ(#12、#17、およびCTM)を、異なる染色濃度およびインキュベーション時間で分析した。データは、総細胞/mL、生細胞/mL、および生存率の3つの主要属性について分析された。
SYNB1020(N-アセチルグルタミン酸シンターゼ酵素ArgAのフィードバック耐性バージョンargAfbr、および欠失されたアルギニンリプレッサーArgRを含む;Kurtz et al., An Engineered E.coli Nissle Improves Hyperammonemia and Survival in Mice and Shows Dose-dependent Exposure in Healthy Humans、2019年を参照)は、5、7.5、10および15uMのSytox Green濃度でインキュベートされた。各濃度について、2、4、6および8分間染色を行った。総細胞/mLは、染色濃度の違いまたは時間の経過とともに変化しなかった。(図13A-13C)。
PKU凍結乾燥株SYNB1618のいくつかの希釈液を試験し、細胞カウントを求め、線形性について分析した。カウントされた細胞が861~2547個の範囲では、R2=0.84であり、この範囲の逆算されたタイター(back-calculated titers)のCVは9.85%であった。賦形剤(50mMTris緩衝液中の10%トレハロース、pH7.5)を含むSYNB1618も、生細胞/mLの線形性について試験され、同じ線形範囲が適用可能であった。(図15A-15D)。
Claims (112)
- 治療用分子を産生するための1つ以上の遺伝子を含む所定の数の遺伝子操作された細菌細胞を含む医薬組成物であって、細菌細胞の数は生細胞計数によって決定され、生細胞計数はコロニー形成単位(CFU)計数よりも治療活性のより正確な尺度を提供する。
- 所定数の遺伝子操作されたバクテリアが、生細胞計数によって測定されるように、1x108~1x1013の細胞である、請求項1に記載の医薬組成物。
- 所定数の遺伝子操作されたバクテリアが、生細胞計数によって測定されるように、1x109~1x1013の細胞である、請求項1または2に記載の医薬組成物。
- 所定数の遺伝子操作されたバクテリアが、生細胞計数によって測定されるように、約1×1011の生細胞、約1.1×1011の生細胞、約1.2×1011の生細胞、約1.3×1011の生細胞、約1.4×1011の生細胞、約1.5×1011の生細胞、約1.6×1011の生細胞、約1.7×1011の生細胞、約1.8×1011の生細胞、約1.9×1011の生細胞、約2×1011の生細胞、約2.1×1011の生細胞、約2.2×1011の生細胞、約2.3×1011の生細胞、約2.4×1011の生細胞、約2.5×1011の生細胞、約2.6×1011の生細胞、約2.7×1011の生細胞、約2.8×1011の生細胞、約2.9×1011の生細胞、約3×1110の生細胞、約3.1×1011の生細胞、約3.2×1011の生細胞、約3.3×1011の生細胞、約3.4×1011の生細胞、約3.5×1011の生細胞、約3.6×1011の生細胞、約3.7×1011の生細胞、約3.8×1011の生細胞、約3.9×1011の生細胞、約4×1011の生細胞、約5×1011の生細胞、約6×1011の生細胞、約7×1011の生細胞、約8×1011の生細胞、または約9×1011の生細胞である、請求項1~3に記載の医薬組成物。
- 所定数の遺伝子操作されたバクテリアが、生細胞計数によって測定されるように、約1×1012の生細胞、約1.1×1012の生細胞、約1.2×1012の生細胞、約1.3×1012の生細胞、約1.4×1012の生細胞、約1.5×1012の生細胞、約1.6×1012の生細胞、約1.7×1012の生細胞、約1.8×1012の生細胞、約1.9×1012の生細胞、約2×1012の生細胞、約2.1×1012の生細胞、約2.2×1012の生細胞、約2.3×1012の生細胞、約2.4×1012の生細胞、約2.5×1012の生細胞、約2.6×1012の生細胞、約2.7×1012の生細胞、約2.8×1012の生細胞、約2.9×1012の生細胞、約3×1012の生細胞、約3.1×1012の生細胞、約3.2×1012の生細胞、約3.3×1012の生細胞、約3.4×1012の生細胞、約3.5×1012の生細胞、約3.6×1012の生細胞、約3.7×1012の生細胞、約3.8×1012の生細胞、約3.9×1012の生細胞、約4×1012の生細胞、約4.1×1012の生細胞、約4.2×1012の生細胞、約4.3×1012の生細胞、約4.4×1012の生細胞、約4.5×1012の生細胞、約4.6×1012の生細胞、約4.7×1012の生細胞、約4.8×1012の生細胞、約4.9×1012の生細胞、または約5×1012生細胞である、請求項1~4のいずれか一項に記載の医薬組成物。
- 遺伝子操作されたバクテリアが、被験体における疾患または障害の治療のための1つ以上の非天然遺伝子を含む、請求項1~5のいずれか一項に記載の医薬組成物。
- 前記1つ以上の遺伝子が、誘導性プロモーターに動作可能に連結されている、請求項6に記載の医薬組物。
- 医薬組成物を被験体に投与するとき、前記1つ以上の遺伝子が誘導される、請求項7に記載の医薬組成物。
- 医薬組成物が被験体に投与される前に前記1つ以上の遺伝子が誘導される、請求項7に記載の医薬組成物。
- 遺伝子操作された細菌が、1つ以上のフェニルアラニン代謝酵素(PME)を含む、請求項1~9のいずれか一項に記載の医薬組成物。
- 請求項1~10のいずれかに記載の医薬組成物:であって、遺伝子操作された細菌は、
a) フェニルアラニンアンモニアリアーゼ(PAL)をコードする1つ以上の遺伝子であって、PALをコードする遺伝子が、本質的にPAL遺伝子と関連していない誘導性プロモーターと動作可能に連結されているものであり、
b) フェニルアラニントランスポーターをコードする1つ以上の遺伝子であって、フェニルアラニントランスポーターをコードする遺伝子が、本質的にフェニルアラニントランスポーター遺伝子と結合していない誘導性プロモーターと動作可能に結合しているもの、を含む。 - 前記細菌が、さらにL-アミノ酸デアミナーゼ(LAAD)をコードする1つ以上の遺伝子を含み、LAADをコードする遺伝子は、本質的にLAAD遺伝子と関連していない誘導性プロモーターと動作可能に連結されている、請求項11に記載の医薬組成物。
- PALをコード化する遺伝子と動作可能に連結されたプロモーターとフェニルアラニントランスポーターをコード化する遺伝子と動作可能に連結されたプロモーターが、同じプロモーターの別々のコピーである、請求項11または12に記載の薬学的組成物。
- PALをコード化する遺伝子およびフェニルアラニントランスポーターをコード化する遺伝子が、単一のプロモーターに機能的に連結されている、請求項11または12に記載の医薬組成物。
- PALをコード化する遺伝子およびフェニルアラニントランスポーターをコード化する遺伝子が、異なるプロモーターと作動可能に連結されている、請求項11または12に記載の医薬組成物。
- LAADをコード化する遺伝子、PALをコード化する遺伝子、およびフェニルアラニントランスポーターをコード化する遺伝子が、同じプロモーターの別々のコピーと作動可能に連結されている、請求項12または13に記載の医薬組成物。
- LAADをコード化する遺伝子が、PALをコード化する遺伝子およびフェニルアラニントランスポーターをコード化する遺伝子と作動可能に連結されたプロモーターとは異なるプロモーターと作動可能に連結されている、請求項12~15のいずれか一項に記載の医薬組成物。
- PALをコード化する遺伝子およびフェニルアラニントランスポーターをコード化する遺伝子と作動可能に連結されたプロモーターまたは複数のプロモーターが、哺乳動物の消化管に見出される外因性環境条件によって直接的または間接的に誘導される、請求項11~17のいずれか一項に記載の医薬組成物。
- フェニルアラニントランスポーターをコード化する遺伝子に作動可能に連結されたプロモーターは、低酸素または嫌気性条件下で誘導されるプロモーター、熱調節プロモーター、およびアラビノース、IPTG、テトラサイクリン、またはラムノースによって誘導されるプロモーターから選択される、請求項11~18のいずれか一項に記載の医薬組成物。
- PALをコード化する遺伝子が、低酸素または嫌気性条件下で誘導されるプロモーター、熱調節プロモーター、およびアラビノース、IPTG、テトラサイクリン、またはラムノースによって誘導されるプロモーターから選択されるプロモーターと作動可能に連結された、請求項11~19のいずれか一項に記載の医薬組成物。
- LAADをコード化する遺伝子に作動可能に連結されたプロモーターは、低酸素または嫌気性条件下で誘導されるプロモーター、熱調節プロモーター、およびアラビノース、IPTG、テトラサイクリン、またはラムノースによって誘導されるプロモーターから選択される、請求項12~20のいずれか一項に記載の医薬組成物。
- 熱調節プロモーターは、37oC~42oCの間の温度で誘導される、請求項19~21のいずれか一項に記載の医薬組成物。
- 熱調節プロモーターは、ラムダCI誘導性プロモーターである、請求項19~22のいずれか一項に記載の医薬組成物。
- 遺伝子操作された細菌は、温度感受性CIリプレッサー突然変異体をコード化する1つ以上の遺伝子をさらに含む、請求項11~23のいずれか一項に記載の医薬組成物。
- 温度感受性CIリプレッサー突然変異体がCI857である、請求項24に記載の医薬組成物。
- 温度感受性CIリプレッサー突然変異体をコード化する遺伝子およびLAADをコード化する遺伝子が、同じプロモーターの制御下にある請求項24または25のいずれかに記載の遺伝子操作された細菌。
- PALをコード化する遺伝子およびフェニルアラニントランスポーターをコード化する遺伝子と作動可能に連結されたプロモーターまたは複数のプロモーターが、低酸素または嫌気性条件下で直接的または間接的に誘導される、請求項11~16のいずれか一項に記載の医薬組成物。
- プロモーターまたは複数のプロモーターが、FNR応答性プロモーター、ANR応答性プロモーター、およびDNR応答性プロモーターからなる群より選択される、請求項27に記載の医薬組成物。
- フェニルアラニンプロモーターをコード化する遺伝子が、細菌中の染色体上に位置する、請求項11~28のいずれか一項に記載の医薬組成物。
- フェニルアラニンプロモーターをコード化する遺伝子が、細菌中のプラスミド上に位置する、請求項11~28のいずれか一項に記載の医薬組成物。
- PALをコード化する遺伝子が細菌中の染色体上に位置する、請求項11~30のいずれか一項に記載の医薬組成物。
- PALをコード化する遺伝子が細菌中のプラスミド上に位置する、請求項11~30のいずれか一項に記載の医薬組成物。
- LAADをコード化する遺伝子が、細菌中の染色体上に位置する、請求項12~32のいずれか一項に記載の医薬組成物。
- LAADをコード化する遺伝子が、細菌中のプラスミド上に位置する、請求項12~32のいずれか一項に記載の医薬組成物。
- PALがアナベナ・バリアビリス(PAL1)由来またはフォトラブダス・ルミネッセンス(PAL3)由来である、請求項11~34のいずれか一項に記載の医薬組成物。
- フェニルアラニントランスポーターがPhePである、請求項11~35のいずれか一項に記載の医薬組成物。
- 遺伝子操作された細菌が、抗癌分子、例えば脱アデニル酸シクラーゼ遺伝子またはインターフェロン遺伝子(STING)アゴニストの刺激因子を産生することができる酵素を産生するための少なくとも1つの遺伝子を含む、請求項1~9のいずれか一項に記載の医薬組成物。
- 遺伝子操作された細菌が、改変アルギニン生合成経路、例えば、欠失アルギニンリプレッサー、改変アルギニンリプレッサー結合部位、および/またはアルギニンフィードバック耐性N-アセチルグルタミン酸合成酵素突然変異をコード化する遺伝子を含む、請求項1~9のいずれか一項に記載の医薬組成物。
- 遺伝子操作された細菌が、細菌が哺乳動物の腸内に存在するときに補完される遺伝子中の栄養要求株である、請求項1~38のいずれか一項に記載の医薬組成物。
- 前記細菌がジアミノピメリン酸中またはチミジン中の栄養要求株である、請求項39に記載の遺伝子操作された細菌。
- 細菌に毒性のある物質をコード化する遺伝子を持つように細菌がさらに操作され、遺伝子は、環境因子または信号の有無によって直接的または間接的に誘導されるプロモーターの制御下にある、請求項1~40のいずれか一項に記載の遺伝子操作された細菌。
- 前記細菌が、バクテロイデス、ビフィズス菌、クロストリジウム、大腸菌類、ラクトバチルス、および乳酸球菌からなる群より選択される、請求項1~41のいずれか一項に記載の医薬組成物。
- 前記細菌が、大腸菌株ニッスルである、請求項42に記載の医薬組成物。
- 経口または直腸投与のために処方された請求項1~43のいずれか一項に記載の組成物。
- 遺伝子操作されたバクテリアが、凍結乾燥製剤、再構成された凍結乾燥製剤、固形製剤、または固形経口製剤である、請求項1~44のいずれか一項に記載の医薬組成物。
- 遺伝子操作されたバクテリアが、液体製剤または凍結液体製剤である、請求項1~44のいずれか一項に記載の医薬組成物。
- 遺伝子操作されたバクテリアを噴霧乾燥する、請求項1~44のいずれか一項に記載の医薬組成物。
- 1~100mMのトリス緩衝液をさらに含む、請求項1~47のいずれか一項に記載の医薬組成物。
- 1~50mMのトリス緩衝液をさらに含む、請求項1~47のいずれか一項に記載の医薬組成物。
- 1~10mMのトリス緩衝液をさらに含む、請求項1~47のいずれか一項に記載の医薬組成物。
- 1~20%のトレハロースをさらに含む、請求項1~50のいずれか一項に記載の医薬組成物。
- 10~20%のトレハロースをさらに含む、請求項1~50のいずれか一項に記載の医薬組成物。
- pHが6.0~8.0である請求項1~52のいずれか一項に記載の医薬組成物。
- pHが6.0~7.0である請求項1~53のいずれか一項に記載の医薬組成物。
- pHが7.0~8.0である請求項1~53のいずれか一項に記載の医薬組成物。
- 組成物が2-8℃で保存される場合少なくとも1ヵ月間安定である、請求項1~55のいずれか一項に記載の医薬組成物。
- 組成物が少なくとも3ヵ月間安定である、請求項56に記載の医薬組成物。
- 組成物が少なくとも6ヵ月間安定である、請求項57に記載の医薬組成物。
- 組成物が少なくとも9ヵ月間安定である、請求項58に記載の医薬組成物。
- 組成物が少なくとも12ヵ月間安定である、請求項59に記載の医薬組成物。
- 室温および相対湿度60%で保存した場合、組成物が少なくとも1ヵ月間安定である、請求項1~60のいずれか一項に記載の医薬組成物。
- 組成物が凍結液体中で遺伝子操作されたバクテリアを有する医薬組成物と同様の安定性を示す、請求項1~61のいずれか一項に記載の医薬組成物。
- 組成物が凍結液体中の同数の生細胞を有する医薬組成物と同様の活性を有する、請求項1~62のいずれか一項に記載の医薬組成物。
- 組成物が凍結した液体状の遺伝的に操作されたバクテリアを含む組成物と同じ割合の生細胞を有し、生細胞の割合は、総細胞数で割った生細胞の数である、請求項1~63のいずれか一項に記載の医薬組成物。
- 生細胞の割合が少なくとも60%であって、生細胞の割合は、総細胞数で割った生細胞数の数である、請求項64に記載の医薬組成物。
- 生細胞の割合が少なくとも65%である請求項65に記載の医薬組成物。
- 生細胞の割合が少なくとも70%である請求項66に記載の医薬組成物。
- 生細胞の割合が少なくとも75%である請求項67に記載の医薬組成物。
- 生細胞の割合が少なくとも80%である請求項68に記載の医薬組成物。
- 生細胞の割合が少なくとも82%である請求項69に記載の医薬組成物。
- 生細胞の割合が少なくとも84%である請求項70に記載の医薬組成物。
- 医薬組成物が少なくとも約0.5μmol/時/109細胞の速度でTCAを産生することができる、請求項1~36または39~71のいずれか一項に記載の医薬組成物。
- TCA産出速度が少なくとも約1.0μmol/時/109細胞である、請求項72に記載の医薬組成物。
- TCA産出速度が少なくとも約1.9±1.2μmol/時/109細胞である、請求項1~36または39~71のいずれか一項に記載の医薬組成物。
- TCA産出速度がおよそ1.5~10.0μmol/時/109細胞である、請求項73に記載の医薬組成物。
- TCA産出速度がおよそ1.5~5.0μmol/時/109細胞である、請求項75に記載の医薬組成物。
- 医薬組成物が、約1.0μmol/時/109細胞の速度でPPAを産生することができる、請求項1~36または39~76のいずれか一項に記載の医薬組成物。
- PPA産出速度が少なくとも約1.5μmol/時/109細胞である、請求項77に記載の医薬組成物。
- PPA産出速度が少なくとも約2.9±0.7μmol/時/109細胞である、請求項1~36または39~76のいずれか一項に記載の医薬組成物。
- PPA産出速度が約2.0~10.0μmol/時/109細胞である、請求項79に記載の医薬組成物。
- PPA産出速度が約2.0~5.0μmol/時/109細胞である、請求項80に記載の医薬組成物。
- バクテリアが、制御と比較して増加した馬尿酸(例えば、HAまたは標識D5-HA)を産生することができる、請求項1~36または39~76のいずれか一項に記載の医薬組成物。
- 医薬組成物が、約1.9×108±1.8×108EU/g以下のエンドトキシンを含む、請求項1~82のいずれか一項に記載の医薬組成物。
- 医薬組成物が、約4.0×108EU/g以下のエンドトキシンを含む請求項1~82のいずれか一項に記載の医薬組成物。
- 医薬組成物が、約3.0×108EU/g以下のエンドトキシンを含む、請求項84に記載の医薬組成物。
- 医薬組成物が、約2.0×108EU/g以下のエンドトキシンを含む、請求項85に記載の医薬組成物。
- 医薬組成物が、約1.0×108 EU/g以下のエンドトキシンを含む、請求項86に記載の医薬組成物。
- 医薬組成物が約5×107EU/g以下のエンドトキシンを含む、請求項87に記載の医薬組成物。
- 細菌がカプセルまたは錠剤中に処方される、請求項1~88のいずれかに記載の医薬組成物。
- 請求項1~89のいずれかに記載の薬学的組成物を投与することを含む被験体を治療する方法。
- 治療用分子を産生するための1つ以上の遺伝子を含む遺伝子操作されたバクテリアを含む医薬組成物の活性を決定するための方法であって、この方法は遺伝子操作されたバクテリアの生細胞数を決定することを含み、その生細胞数がCFUよりもより正確な治療活性の測定値を提供する、方法。
- 治療用分子を産生するための1つ以上の遺伝子を含む遺伝子操作されたバクテリアを含む医薬組成物の効力を決定するための方法であって、この方法は遺伝子操作されたバクテリアの生細胞数を決定することを含み、その生細胞数がCFUよりもより正確な効力の測定値を提供する、方法。
- 請求項92の記載の方法に従って製造された遺伝子操作された細菌。
- 請求項1~89のいずれかに記載の医薬組成物の活性を決定する方法であって、その方法は生細胞数を決定することを含み、生細胞数がCFUよりもバクテリア活性のより正確な測定値を提供する、方法。
- 請求項1~89のいずれかに記載の医薬組成物の効力を測定する方法であって、その方法は生細胞数を測定することを含み、生細胞数がCFUよりも正確な効力の測定値を提供する、方法。
- 治療用分子を産生するための1つ以上の遺伝子を含む遺伝子操作された細菌を含む医薬組成物を製造する方法であって、細菌を凍結乾燥し生細胞数によって細菌細胞数を測定することを含み、生細胞数がCFUよりも細菌活性のより正確な測定値を提供する、方法。
- 治療用分子を産生するための1つ以上の遺伝子を含む遺伝子操作された細菌を含み、細菌を凍結乾燥し、生細胞数によって細菌細胞数を測定することを含む医薬組成物を製造する方法であって、細菌のCFU数を測定することを含む方法と比較して、CFU数が減少した医薬組成物を提供する、方法。
- 遺伝子操作された細菌を含む医薬組成物のCFU数を減少させる方法であって、細菌を凍結乾燥し、生細胞数によって細菌細胞数を測定することからなり、液体中で細菌を凍結し、CFU数を測定することを含む方法と比較して、CFU数を減少していることを特徴とする方法。
- 請求項98に記載の方法に従って製造された遺伝子操作された細菌。
- 請求項1~89のいずれかに記載の医薬組成物を製造する方法であって、生細胞数によって細菌細胞数の決定をすることを含み、生細胞数がCFUよりも細菌活性のより正確な測定値を提供することを特徴とする方法。
- 生細胞計数によって決定されるように、遺伝子操作された細菌の活性を非未変性の細菌と比較して維持および/または増加させる方法であって、細菌を凍結乾燥することを含む、方法。
- 請求項101に記載の方法に従って製造される遺伝子操作された細菌。
- 高フェニルアラニン血症の低減又は高フェニルアラニン血症に関連する疾患の治療に使用する請求項1~36又は39~89のいずれか一項に記載の組成物。
- 疾患が、フェニルケトン尿症、古典的または典型的フェニルケトン尿症、非定型フェニルケトン尿症、永久的に軽度の高フェニルアラニン血症、非フェニルケトン尿性高フェニルアラニン血症、フェニルアラニン水酸化酵素欠損症、補因子欠損症、ジヒドロプテリジンレダクターゼ欠損症、テトラヒドロプテリンシンターゼ欠損症、瀬川病、および肝疾患からなる群より選択される、請求項103に記載の組成物の使用。
- 高アンモニア血症の減少または高アンモニア血症に関連する疾患の治療に使用する請求項1~9、38~71または83~89のいずれかに記載の組成物。
- 疾患が、尿素サイクル不良、癌、アルギニノコハク酸尿症、アルギナーゼ欠損症、カルバモイルリン酸合成酵素欠損症、シトルリン血症、N-アセチルグルタミン酸合成酵素欠損症、オルニチン、トランスカルバミラーゼ欠損症、肝性脳症、肝不全、慢性肝不全、有機酸不良、イソ吉草酸尿症、3-メチルクロトニルグリシン尿症、メチルマロン酸血症、プロピオン酸尿症、脂肪酸酸化欠損症、カルニチンサイクル欠損症、カルニチン欠損症、β-酸化欠損症、リジン尿性タンパク質不耐症、ピロリン-5-カルボン酸合成酵素欠損症、ピルビン酸カルボキシラーゼ欠損症、オルニチンアミノトランスフェラーゼ欠損症、炭酸脱水酵素欠損症、高インスリン血症-高アンモニア血症症候群、ミトコンドリア障害、バルプロ酸療法、アスパラギナーゼ療法、完全非経口栄養法、グリシン含有溶液による膀胱鏡検査、肺/骨髄移植後、門脈体循環シャント、尿路感染症、尿管拡張、多発性骨髄腫、化学療法、感染症、神経因性膀胱、腸内細菌の過剰増殖、ハンチントン病、痙攣、運動失調、脳卒中様病変、昏睡、精神病、視力低下、急性脳症、嘔吐, 呼吸性アルカローシス、低体温からなる群より選択される、請求項105に記載の組成物。
- 請求項1~9、37、39~71、または83~89のいずれか一項に記載の癌の治療に使用する組成物。
- 癌が副腎癌、副腎皮質癌、肛門癌、虫垂癌、胆管癌、膀胱癌、骨癌(例えばユーイング肉腫、骨肉腫、悪性線維性組織球腫)、脳癌(例えば星状細胞腫、脳幹神経膠腫、頭蓋咽頭腫、上衣腫)、気管支腫瘍、中枢神経系腫瘍、乳癌、キャッスルマン病、子宮頸癌、大腸癌、直腸癌、結腸直腸癌、子宮内膜癌、食道癌、眼癌、胆嚢癌、胃腸癌、消化管カルチノイド腫瘍、消化管間質腫瘍、妊娠性絨毛性疾患、心臓癌、カポジ肉腫、腎臓癌、喉頭癌、下咽頭癌、白血病(例えば急性リンパ性白血病、急性骨髄性白血病、慢性リンパ性白血病、慢性骨髄性白血病)、肝臓がん、肺がん、リンパ腫、(例えば、AIDS関連リンパ腫、バーキットリンパ腫、皮膚T細胞リンパ腫、ホグキンリンパ腫、非ホグキンリンパ腫、原発性中枢神経系リンパ腫)、悪性中皮腫、多発性骨髄腫、骨髄異形成症候群、鼻腔癌、副鼻腔癌、鼻咽頭癌、神経芽腫、口腔がん、中咽頭癌、骨肉腫、卵巣癌、膵臓癌、陰茎癌、下垂体腫瘍、前立腺癌、網膜芽細胞腫、横紋筋肉腫、ラブドイド腫瘍、唾液腺癌、肉腫、皮膚癌(例えば、基底細胞癌、黒色腫)、小腸癌、胃癌、奇形腫、精巣癌、咽頭癌、胸腺癌、甲状腺癌、異常小児癌、尿道癌、子宮癌、子宮肉腫、膣がん、外陰がん、ワルデンシュトレームマクログロブリン血症、およびウィルムス腫瘍からなる群より選択される、請求項107に記載の組成物。
- 所定の数の遺伝子操作された細菌を含む医薬組成物で患者を治療する方法であって、患者が疾患または障害に罹患している場合、その方法は以下のステップを含む。
所定の数の遺伝子操作された細菌を含む医薬組成物を投与すること。 - 請求項1~89のいずれか一項に記載の医薬組成物を使用する、請求項109に記載の方法。
- 遺伝子操作された細菌を含む医薬組成物で患者を治療する方法であって、患者が疾患または障害に罹患している場合、その方法は以下のステップを含む。
遺伝子操作された細菌を含む医薬組成物の入手すること、
医薬品組成物の生細胞数の測定をすること、
所定数の生細胞に相当する量の医薬組成物を投与すること。 - 遺伝子操作された細菌を含む医薬組成物を製造するための方法であって、組成物の生細胞数を測定することを含み、得られた医薬組成物が、同じ医薬組成物のCFU数を測定することを含む方法を使用して製造された医薬組成物と比較して減少したCFU数を有する、方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962840281P | 2019-04-29 | 2019-04-29 | |
US62/840,281 | 2019-04-29 | ||
US201962946785P | 2019-12-11 | 2019-12-11 | |
US62/946,785 | 2019-12-11 | ||
PCT/US2020/030468 WO2020223345A1 (en) | 2019-04-29 | 2020-04-29 | Enumeration of genetically engineered microorganisms by live cell counting techniques |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022530503A true JP2022530503A (ja) | 2022-06-29 |
JPWO2020223345A5 JPWO2020223345A5 (ja) | 2023-05-12 |
Family
ID=70805206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021563687A Withdrawn JP2022530503A (ja) | 2019-04-29 | 2020-04-29 | 遺伝子操作された微生物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220257732A1 (ja) |
EP (1) | EP3963046A1 (ja) |
JP (1) | JP2022530503A (ja) |
KR (1) | KR20220003030A (ja) |
WO (1) | WO2020223345A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116847860A (zh) | 2020-12-31 | 2023-10-03 | 同生运营公司 | 经工程化以减轻高苯丙氨酸血症的微生物 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
US9084434B2 (en) | 2006-09-27 | 2015-07-21 | Little Calumet Holdings Llc | Probiotic oral dosage forms |
WO2016141108A1 (en) | 2015-03-02 | 2016-09-09 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
BR112017011923A2 (pt) | 2014-12-05 | 2018-02-27 | Synlogic Inc | bactéria modificada para tratar doenças associadas com hiperamonemia |
US9889164B2 (en) | 2014-12-05 | 2018-02-13 | Synlogic, Inc. | Bacteria engineered to treat a disease or disorder |
AU2016276973B2 (en) | 2015-06-10 | 2022-09-01 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid |
EP3307879A2 (en) | 2015-06-10 | 2018-04-18 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
US11291693B2 (en) | 2015-06-25 | 2022-04-05 | Synlogic Operating Company, Inc. | Bacteria engineered to treat metabolic diseases |
US20170216370A1 (en) | 2015-07-31 | 2017-08-03 | Synlogic, Inc. | Bacteria engineered to treat disorders involving propionate catabolism |
US11273184B2 (en) | 2015-08-31 | 2022-03-15 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders in which oxalate is detrimental |
JP2018532412A (ja) | 2015-10-30 | 2018-11-08 | シンロジック オペレーティング カンパニー インコーポレイテッド | 消化管炎症低下および/または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌 |
WO2017087580A1 (en) | 2015-11-16 | 2017-05-26 | Synlogic, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
EP3402497A1 (en) | 2016-01-11 | 2018-11-21 | Synlogic Operating Company, Inc. | Bacteria engineered to treat metabolic diseases |
WO2017123676A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof |
WO2017136795A1 (en) | 2016-02-04 | 2017-08-10 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with tryptophan metabolism |
AU2017213646A1 (en) | 2016-02-04 | 2018-08-23 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
WO2017139697A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
EP3565566A1 (en) | 2017-01-06 | 2019-11-13 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
JP7358245B2 (ja) | 2017-06-21 | 2023-10-10 | シンロジック オペレーティング カンパニー インコーポレイテッド | 障害の処置のための細菌 |
WO2019014391A1 (en) | 2017-07-12 | 2019-01-17 | Synlogic Operating Company, Inc. | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNOMODULATORS AND ANTICANCER THERAPEUTIC AGENTS IN TUMOR CELLS |
-
2020
- 2020-04-29 US US17/607,248 patent/US20220257732A1/en active Pending
- 2020-04-29 JP JP2021563687A patent/JP2022530503A/ja not_active Withdrawn
- 2020-04-29 EP EP20727879.7A patent/EP3963046A1/en active Pending
- 2020-04-29 KR KR1020217038657A patent/KR20220003030A/ko unknown
- 2020-04-29 WO PCT/US2020/030468 patent/WO2020223345A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020223345A1 (en) | 2020-11-05 |
KR20220003030A (ko) | 2022-01-07 |
US20220257732A1 (en) | 2022-08-18 |
EP3963046A1 (en) | 2022-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6843768B2 (ja) | 高フェニルアラニン血症を低減させるように操作された細菌 | |
US20220362309A1 (en) | Microorganisms engineered to reduce hyperphenylalaninemia | |
EP4271806A1 (en) | Microorganisms engineered to reduce hyperphenylalaninemia | |
US20240102024A1 (en) | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | |
JP2022530503A (ja) | 遺伝子操作された微生物 | |
US20240197843A1 (en) | Bacteria engineered to treat disorders in which oxalate is detrimental | |
US20240110191A1 (en) | Engineered microorganisms | |
US20230092431A1 (en) | Bacteria engineered to treat disorders in which oxalate is detrimental | |
US20230174926A1 (en) | Bacteria engineered to treat disorders involving the catabolism of leucine | |
WO2023250478A1 (en) | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | |
CN117083068A (zh) | 经工程化以治疗其中草酸盐有害的病症的细菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230428 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230428 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20231011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231011 |